AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology

Start with:

✓Flexible Plans • $39/mo or $29/mo annual

✓AI + real-time funding intelligence

✓Never see duplicates in your feed

INDUSTRY FIRST

BioDirection®, Inc. Closes $18 Million Series C Financing Led by Shepherd Kaplan Krochuk, LLC

Jul 01, 2020•about 5 years ago

Amount Raised

$18 Million

Round Type

series c

Boston

Description

BioDirection®, Inc. d/b/a NanoDiagnosticsTM, Inc. (NanoDxTM), a privately held medical device company developing cutting-edge and rapid point-of-care in-vitro diagnostic products for the objective detection, diagnosis and management of Traumatic Brain Injury (TBI), virus detection and inflammatory disease today announced that it has closed an $18 million Series C Convertible Preferred Stock Financing. The financing was led by the Alternative Investment division of Shepherd Kaplan Krochuk, LLC (SKK), a diversified Wealth and Asset Management firm located in Boston, Massachusetts.

Company Information

Company

Bio Direction, Inc.

Location

Boston, Massachusetts, United States

About

BioDirection® is a privately held medical device company developing cutting-edge and rapid point-of-care products for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company's lead product, the NanoDxTM System, delivers biologically based results shown to accurately confirm a concussion in less than 2 minutes. BioDirection's platform utilizes a patented nano biosensor technology with the potential for use in a wide range of applications in point-of-care diagnostics.

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech